
Please try another search
Symbol | Exchange | Currency | ||
---|---|---|---|---|
GILD | NASDAQ | USD | Real-time | |
GILD | Mexico | MXN | Delayed | |
GGILD | Milan | EUR | Real-time | |
GILD | Xetra | EUR | Delayed | |
GILD | Frankfurt | EUR | Delayed | |
GILD | TradeGate | EUR | Delayed | |
GILD | Santiago | USD | Delayed | |
GILDCL | Santiago | CLP | Delayed | |
GILD | Buenos Aires | ARS | Delayed | |
GILD | Vienna | EUR | Delayed |
Gilead Sciences (NASDAQ: GILD) resubmitted the New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for lenacapavir, an investigational, long-acting HIV-1 capsid inhibitor, for...
Gilead Sciences, Inc. (NASDAQ: NASDAQ:GILD) climbed on Wednesday, even as the S&P 500 ended the day with losses. On CNBC's "Options Action," Tony Zhang said that Gilead Sciences traded nearly 2.5...
Gilead has spent over $40 billion in the past five years with little to show for it, yet the high-yielding stock offers a haven to investors in this bear market.
By Deena Beasley (Reuters) – Gilead Sciences Inc’s Trodelvy extended by 1.5 months, or 34%, the length of time women with advanced stages of the most common type of breast cancer lived without...
HOOKIPA Pharma Inc. (HOOK) today reported financial results and business highlights for the first quarter of 2022.“We observed strong external validation of our novel arenaviral platform in the first...
Gilead Sciences (NASDAQ:GILD) reported its Q1 results, with EPS of $2.12 coming in better than the consensus estimate of $1.81. Revenue grew 3% year-over-year to $6.6 billion, compared to the...
Gilead Sciences (NASDAQ:GILD) reported Q1 EPS of $2.12, $0.31 better than the analyst estimate of $1.81. Revenue for the quarter came in at $6.6 billion versus the consensus estimate of $6.28...
Investing.com - Gilead (NASDAQ:GILD) reported on Thursday first quarter earnings that beat analysts' forecasts and revenue that topped expectations. Gilead announced earnings per share of $2.12 on...
Gilead Sciences, Inc. (Nasdaq: NASDAQ:GILD) announced that the U.S. Food and Drug Administration (FDA) decided to remove its partial clinical hold on the company's studies investigating magrolimab in...
On CNBC’s "Mad Money Lightning Round," Jim Cramer said he likes Healthcare Realty Trust Incorporated (NYSE: HR) as the company’s merger with Healthcare Trust of America, Inc. (NYSE:...
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review